ABCL News and Press, AbCellera Biologics Inc. From 02/10/22

Bebtelovimab neutralizes Omicron, including subvariant BA.2, as demonstrated by pseudovirus and/or authentic virus data AbCellera (Nasdaq: ABCL) today announced Eli Lilly and Company (Lilly) has entered into a purchase agreement with the U.S. government to supply up to 6...

AbCellera (Nasdaq: ABCL) announced today that it will report full year 2021 financial results after market close on Thursday, February 24, 2022 and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. The live webcast of the earnings ...

Intercontinental Exchange will add 138 securities to the ICE Biotechnology index and delete 26 as part of the annual reconstitution, effective prior to market open on December 20. Notable additions: Aurinia Pharmaceuticals (NASDAQ:AUPH), Anavex Life Sciences (NASDAQ:AVXL), Sesen Bio...

AbCellera Biologics (ABCL +5.2%)jumps after the director Andrew Lo bought 86,938 shares at $14.02 each. The transaction value amounts to $1.22M. SEC Filing. Earlier, AbCellera rises as beneficiary of COVID antibody cocktail EUA expansion For further details see: AbCellera Biologics up 5...

AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced changes to its Board of Directors with the appointment of Andrew W. Lo, Ph.D., as an independent director and the resignation of John Hamer, Ph....

AbCellera has been pummeled in the market this year, dropping like a stone to the current price of just over $14 a share. I believe this is a huge mistake. AbCellera currently has 131 programs with royalty agreements under contract and that number continues to grow fast. Using a 1...

Shares of AbCellera Biologics (NASDAQ:ABCL) are up 9% in post-market trading, apparently getting a boost from the FDA Emergency Use Authorization expansion earlier in the day for bamlanivimab and etesevimab, developed with Eli Lilly (NYSE:LLY), for COVID-19. The EUA for the antibody...

Expanded EUA includes both treatment of patients with COVID-19 and post-exposure prophylaxis (PEP) in pediatric and infant patients AbCellera (Nasdaq: ABCL) today announced the U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for...

AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, announced today the appointment of Neil Aubuchon as Chief Commercial Officer (CCO). Mr. Aubuchon brings over 20 years of experience in strategic planning, opera...

Stanley Druckenmiller's Duquesne disclosed its updated portfolio position in its recent 13F filing. It has taken new positions in Coupang (NYSE:CPNG) of 15.5M shares, Oscar Health (NYSE:OSCR) of 0.99M shares, AbCellera Biologics (NASDAQ:ABCL) of 0.66M shares and PROCEPT BioRobotics&...